Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum.
Methamphetamine (METH) is a central nervous system psychostimulant with a high potential for abuse. At high doses, METH causes a selective degeneration of dopaminergic terminals in the striatum. Dopamine D2 receptor antagonists and dopamine transporter (DAT) inhibitors protect against neurotoxicity of the drug by decreasing intracellular dopamine content and, consequently, dopamine autoxidation and production of reactive oxygen species. In vitro, amphetamines regulate D2 receptor and DAT functions via regulation of their intracellular trafficking. No data exists on axonal transport of both proteins and there is limited data on their interactions in vivo. The aim of the present investigation was to examine synaptosomal levels of presynaptic D2 autoreceptor and DAT after two different regimens of METH and to determine whether METH affects the D2 autoreceptor-DAT interaction in the rat striatum. We found that, as compared to saline controls, administration of single high-dose METH decreased D2 autoreceptor immunoreactivity and increased DAT immunoreactivity in rat striatal synaptosomes whereas binge high-dose METH increased immunoreactivity of D2 autoreceptor and had no effect on DAT immunoreactivity. Single METH had no effect on D2 autoreceptor-DAT interaction whereas binge METH increased the interaction between the two proteins in the striatum. Our results suggest that METH can affect axonal transport of both the D2 autoreceptor and DAT in an interaction-dependent and -independent manner.
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA. helichauhan@wayne.edu.
Heli
H
Chauhan
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA. bakillinger@wayne.edu.
Bryan A
BA
Killinger
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA. dy0179@wayne.edu.
Cheryl V
CV
Miller
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA. amosz@wayne.edu.
Anna
A
Moszczynska
D000818:Animals; D017660:Autoreceptors; D001370:Axonal Transport / Q000187:drug effects; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins / Q000096:biosynthesis* / Q000276:immunology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D005334:Fever / Q000139:chemically induced; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D020258:Neurotoxicity Syndromes; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis*; D013574:Synaptosomes / Q000276:immunology / Q000378:metabolism
D017660:Autoreceptors; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D017448:Receptors, Dopamine D2; D008694:Methamphetamine; D004298:Dopamine